SCHEMBL3225044

SCHEMBL3225044

O=C(O)N[C@H]1C[C@H]2CCC[C@@H](C1)C2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
USP2 O75604 1/20 0.42
ALOX15 P16050 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
GAA P10253 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPK1 P28482 1/20 0.35
MEN1 O00255 1/20 0.33
CYP2D6 P10635 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
GLS O94925 1/20 0.33
MMP2 P08253 1/20 0.32
MMP8 P22894 1/20 0.32
EPHX1 P07099 5/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
MAPT P10636 1/20 0.32
CYP3A4 P08684 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3212394 1.00 ALDH1A1 (0.42) ALDH1A1USP2ALOX15SMN1; SMN2GAA
SCHEMBL3212398 1.00 ALDH1A1 (0.42) ALDH1A1USP2ALOX15SMN1; SMN2GAA
SCHEMBL19359215 0.91 ALDH1A1 (0.34) ALDH1A1USP2ALOX15SMN1; SMN2KDM4E
SCHEMBL25417100 0.76 CTSK (0.36) ALDH1A1USP2ALOX15SMN1; SMN2KDM4E
SCHEMBL5433245 0.75 EPHX1 (0.44) ALDH1A1SMN1; SMN2GAAKDM4EMMP2
SCHEMBL5433253 0.75 EPHX1 (0.44) ALDH1A1SMN1; SMN2GAAKDM4EMMP2
SCHEMBL5433248 0.75 EPHX1 (0.44) ALDH1A1SMN1; SMN2GAAKDM4EMMP2
SCHEMBL17504487 0.75 EPHX1 (0.44) ALDH1A1SMN1; SMN2GAAKDM4EMMP2
SCHEMBL21221593 0.74 TRPV1 (0.52) CYP2D6
SCHEMBL897214 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710077-B2 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-04-29 US disclosed
EP-2102164-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI AVENTIS (FR) 2010-12-01 EP disclosed
US-20100056553-A1 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-03-04 US disclosed
EP-2102164-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-09-23 EP disclosed
WO-2008077556-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056553-A1 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 ALDH1A1 3048/4885USP2 3261/4885ALOX15 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.